載入...
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Epidermal growth factor receptor (EGFR) is a validated target in different human malignancies. EGFR tyrosine kinase inhibitors (TKIs) are known to contribute considerably to the extension of progression‐free survival in EGFR‐mutant non‐small cell lung cancer and monoclonal antibodies (mAbs) targetin...
Na minha lista:
| 發表在: | Mol Oncol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528378/ https://ncbi.nlm.nih.gov/pubmed/22189054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.11.009 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|